Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Bal Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹88.60
High
₹92.49
Price Summary
| Previous Close | ₹89.31 |
|---|---|
| Day's Range | ₹88.60 - ₹92.49 |
| Open | ₹88.60 |
| 52 Week Range | ₹60.00 - ₹102.99 |
| Volume | 1,41,079 |
| Market Cap | ₹0.00 |
| Previous Close | ₹89.44 |
|---|---|
| Day's Range | ₹89.23 - ₹94.00 |
| Open | ₹94.00 |
| 52 Week Range | ₹59.69 - ₹112.97 |
| Volume | 4,299 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 126.00 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.38 |
| Price/Earning (TTM) | 22.06 |
| TTM EPS (₹) | 3.95 |
| P/E Ratio | 18.35 |
| Book Value(₹) | 1.69 |
| PAT Margin (%) | 2.39 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 10.10 |
| Trade Value ( ₹ in Lacs) | 3.85 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.38 |
| Price/Earning (TTM) | 22.06 |
| TTM EPS (₹) | 3.95 |
| P/E Ratio | 18.35 |
| Book Value(₹) | 1.69 |
| PAT Margin (%) | 2.39 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 10.10 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 818.76 | 3030.83 |
| Expenses | N/A | N/A |
| PBT | 25.93 | 51.37 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 54.18 | 72.37 |
About Bal Pharma Ltd.
| Founded | 1987 |
|---|---|
| Managing Director | Shailesh Siroya |
| NSE Symbol | BALPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,65,710.92 | 1,970.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,92,375.79 | 7,419.30 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,654.85 | 4,984.30 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,592.33 | 8,814.80 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,978.90 | 1,397.50 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,613.20 | 1,107.30 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,339.52 | 2,409.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,259.52 | 1,099.40 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,03,472.01 | 2,541.30 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 96,638.09 | 570.60 | 0.00 - 0.00 |
No Records Found
Latest News
Bal Pharma informs about closure of trading window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, Bal Pharma has informed that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st July 2026 and up to 48 hours of the declaration of the unaudited financial results of the Company for the quarter ended 30/06/2026. The date of the Board meeting for declaration of the unaudited financial results will be intimated to the exchange in due course.
The above information is a part of company’s filings submitted to BSE.
Bal Pharma informs about resignation of CS cum CO
Anthem Biosciences informs about transcript of conference call
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.
The above information is a part of company’s filings submitted to BSE.
Mercury Laboratories - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 159.63 | 181.35 | -11.98 | 159.63 | 181.35 | -11.98 | 759.37 | 751.01 | 1.11 |
| Other Income | 0.52 | 1.81 | -71.27 | 0.52 | 1.81 | -71.27 | 19.55 | 10.69 | 82.88 |
| PBIDT | 12.44 | 25.35 | -50.93 | 12.44 | 25.35 | -50.93 | 109.96 | 80.85 | 36.00 |
| Interest | 1.23 | 1.45 | -15.17 | 1.23 | 1.45 | -15.17 | 5.45 | 5.48 | -0.55 |
| PBDT | 11.21 | 23.90 | -53.10 | 11.21 | 23.90 | -53.10 | 100.56 | 75.37 | 33.42 |
| Depreciation | 7.29 | 8.43 | -13.52 | 7.29 | 8.43 | -13.52 | 34.20 | 28.76 | 18.92 |
| PBT | 3.92 | 15.47 | -74.66 | 3.92 | 15.47 | -74.66 | 66.36 | 46.61 | 42.37 |
| TAX | 0.94 | 5.80 | -83.79 | 0.94 | 5.80 | -83.79 | 18.03 | 15.16 | 18.93 |
| Deferred Tax | -0.36 | 1.00 | -136.00 | -0.36 | 1.00 | -136.00 | 1.42 | 1.68 | -15.48 |
| PAT | 2.98 | 9.67 | -69.18 | 2.98 | 9.67 | -69.18 | 48.33 | 31.45 | 53.67 |
| Equity | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 |
| PBIDTM(%) | 7.79 | 13.98 | -44.25 | 7.79 | 13.98 | -44.25 | 14.48 | 10.77 | 34.51 |
SMS Pharmaceuticals informs about board meeting
SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Bal Pharma Ltd. is ₹89.31 as of 2026-07-27.
The market capitalisation of Bal Pharma Ltd. is ₹138.64 as of 2026-07-24.
The 1-year return of Bal Pharma Ltd. is -8.28% as of 2026-07-27.
The P/E ratio of Bal Pharma Ltd. is 18.35 as of 2026-07-27.
The 52-week high and low of Bal Pharma Ltd. are ₹102.99 and ₹60.00, respectively, as of 2026-07-27.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
